Scarica l'app Stockscreener
0.9909
0.52%
-0.0052
Dopo l'orario di chiusura:
.99
-0.0009
-0.09%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ITRM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.9961
Aprire:
$0.98
Volume 24 ore:
459.26K
Relative Volume:
1.01
Capitalizzazione di mercato:
$38.80M
Reddito:
-
Utile/perdita netta:
$-35.58M
Rapporto P/E:
-0.3739
EPS:
-2.65
Flusso di cassa netto:
$-42.82M
1 W Prestazione:
+2.15%
1M Prestazione:
+5.59%
6M Prestazione:
-44.95%
1 anno Prestazione:
-15.31%
Intervallo 1D:
$0.9701
$1.0199
Intervallo di 1 settimana:
$0.9685
$1.16
Portata 52W:
$0.808
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Nome
Iterum Therapeutics Plc
Settore
Industria
Telefono
(872) 225-6077
Indirizzo
3 DUBLIN LANDINGS, DUBLIN 1
Confronta ITRM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.9909 | 38.80M | 0 | -35.58M | -42.82M | -2.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-05-28 | Aggiornamento | Gabelli & Co | Sell → Hold |
| 2021-03-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | Downgrade | Gabelli & Co | Buy → Sell |
| 2019-12-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Iterum Therapeutics Plc Borsa (ITRM) Ultime notizie
EVERSANA expands commercialisation portfolio with OS Therapies and Iterum Therapeutics partnerships - pharmaphorum
Citadel Advisors LLC Acquires Shares of 21,207 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics (ITRM) Partners with EVERSANA for U.S. Launc - GuruFocus
Iterum Therapeutics announces partnership with EVERSANA - PharmaLive
Iterum Therapeutics inks deal for ORLYNVAH commercialization By Investing.com - Investing.com Nigeria
Iterum Therapeutics inks deal for ORLYNVAH commercialization - Investing.com
Iterum Therapeutics Inks Partnership With EVERSANA For Commercialization Of ORLYNVAH In US - Nasdaq
Iterum Therapeutics Announces Partnership for Commercialization Services - Yahoo Finance
Pfizer grants Iterum payment extension for FDA-approved antibiotic By Investing.com - Investing.com South Africa
Pfizer grants Iterum payment extension for FDA-approved antibiotic - Investing.com Australia
Iterum Therapeutics Announces Extension of Term of Promissory No - GuruFocus
Iterum Therapeutics (ITRM) Extends $20M Payment Deadline with Pf - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory Note | ITRM Stock News - GuruFocus
Iterum Therapeutics Announces Extension of Term of Promissory Note - The Manila Times
Iterum Therapeutics Announces Extension of $20 Million Regulatory Milestone Payment Deadline with Pfizer to 2029 - Nasdaq
Iterum Gains 3-Year Extension on $20M Pfizer Payment, Strengthens ORLYNVAH Launch Strategy - Stock Titan
Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026 - MSN
When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable? - simplywall.st
Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2025 Earnings Call Transcript - Insider Monkey
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Finance
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Stability Amidst Market Challenges - GuruFocus
Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: - GuruFocus
ITRM Plans Fourth-Quarter Launch for ORLYNVAH in UTI Treatment | - GuruFocus
Iterum Therapeutics (ITRM) Projects Adequate Funding Until 2026 - GuruFocus
Iterum Therapeutics plc SEC 10-Q Report - TradingView
Iterum Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
Transcript : Iterum Therapeutics plc, Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Q1 Earnings Estimate for ITRM Issued By HC Wainwright - Defense World
Iterum Therapeutics’ (ITRM) Buy Rating Reiterated at HC Wainwright - Defense World
Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven? - Yahoo Finance
Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Monday - Defense World
Iterum Therapeutics (ITRM) Receives Buy Rating from HC Wainwrigh - GuruFocus
Iterum Therapeutics (ITRM) Receives Buy Rating from Analyst | IT - GuruFocus
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 - Yahoo Finance
Iterum Therapeutics Earnings Coming May 13: Next-Gen Antibiotics Developer Sets Q1 2025 Update - Stock Titan
Renaissance Technologies LLC Purchases Shares of 438,816 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Check Out Iterum Therapeutics Plc (ITRM)’s Trade Data Rather Than the Analysts’ Views - Sete News
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares - The Manila Times
Iterum Therapeutics Raises $5M from Single Investor: Major Push for Antibiotic Commercialization - Stock Titan
Iterum Therapeutics Plc: Rising -64.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Iterum Therapeutics Plc (ITRM) Becoming More Attractive for Investors - knoxdaily.com
Iterum Therapeutics (ITRM) Secures $5 Million in Direct Offering - GuruFocus
Evaluating ITRM’s financial ratios for a profitable investment - uspostnews.com
Iterum Therapeutics secures $5 million in direct offering - Investing.com
Iterum Therapeutics Announces $5 Million Registered Direct Offering Of Ordinary Shares - marketscreener.com
Iterum Therapeutics plc Announces Definitive Agreement for $5 Million Registered Direct Offering of Shares - Nasdaq
Iterum Therapeutics Secures Critical $5M Funding: ORLYNVAH Drug Launch Plans Accelerate - Stock Titan
ITRM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Iterum Therapeutics Plc (NASDAQ:ITRM) Shares Surged 24.11% In A Week – But Can It Maintain Its Gains? - Marketing Sentinel
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics - The Manila Times
Groundbreaking Research Reveals Age-Specific Patterns in Antibiotic Resistance for UTI Patients - Stock Titan
Iterum Therapeutics Plc Azioni (ITRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):